Click for best price
Eptacog Alfa Recombinant Human Coagulation Factor VIIa Market Size, Share 2023
| Market size in 2022 |
US$ 1166.6 million
|
Forecast Market size by 2029 |
US$ 1431.6 million
|
| Growth Rate |
CAGR of 3.0% |
Number of Pages |
110 Pages |
Recombinant activated factor VII (rFVIIa) binds to exposed tissue factor at the place of tissue and vascular injury. Thrombin generated by this process activates platelets and the coagulation cascade.
This report aims to provide a comprehensive presentation of the global market for Eptacog Alfa (Recombinant Human Coagulation Factor VIIa), with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Eptacog Alfa (Recombinant Human Coagulation Factor VIIa). This report contains market size and forecasts of Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) in global, including the following market information:
Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Market Revenue, 2018-2023, 2024-2030, ($ millions)
Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Market Sales, 2018-2023, 2024-2030, (K Units)
Global top five Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) companies in 2022 (%)
The global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) market was valued at US$ 1166.6 million in 2022 and is projected to reach US$ 1431.6 million by 2029, at a CAGR of 3.0% during the forecast period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
The top three manufacturers of recombinant human coagulation VIIa in the world include Novo Nordisk, LFB SA HEMA Biologics, and GENERIUM, with a total market share of more than 99%. The largest manufacturer is Novo Nordisk, with a market share of more than 95%. North America is the global most important consumer market for recombinant human coagulation VIIa, with a market share of about 45%. In terms of type, the market share of prefilled syringe is over 78%. In the field of application, the market share of congenital hemophilia is about 65%.
We surveyed the Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) manufacturers, suppliers, distributors and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Market, by Type, 2018-2023, 2024-2030 ($ Millions) & (K Units)
Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Market Segment Percentages, by Type, 2022 (%)
60 KIU
50 KIU
Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Market, by Application, 2018-2023, 2024-2030 ($ Millions) & (K Units)
Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Market Segment Percentages, by Application, 2022 (%)
Bleeding
Surgery Assisted
Glanzmann Plateletasthenia
Hemophilia B
Hemophilia A
Head Trauma
Others
Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Market, By Region and Country, 2018-2023, 2024-2030 ($ Millions) & (K Units)
Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Market Segment Percentages, By Region and Country, 2022 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) revenues in global market, 2018-2023 (Estimated), ($ millions)
Key companies Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) revenues share in global market, 2022 (%)
Key companies Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) sales in global market, 2018-2023 (Estimated), (K Units)
Key companies Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) sales share in global market, 2022 (%)
Further, the report presents profiles of competitors in the market, key players include:
BMS
Generium
Novo Nordisk
Shire (Baxter)
Bayer
CSL
Pfizer
Grifols
Biogen
Octapharma
NovoNordisk
Greencross
Kedrion
BPL
Hualan Bio
RAAS
Suzhou Alphamab
Outline of Major Chapters:
Chapter 1: Introduces the definition of Eptacog Alfa (Recombinant Human Coagulation Factor VIIa), market overview.
Chapter 2: Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) market size in revenue and volume.
Chapter 3: Detailed analysis of Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) capacity by region & country.
Chapter 9: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 10: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 11: The main points and conclusions of the report.
| Report Attributes |
Report Details |
| Report Title |
Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Market, Global Outlook and Forecast 2023-2030 |
| Market size in 2022 |
US$ 1166.6 million
|
| Forecast Market size by 2029 |
US$ 1431.6 million
|
| Growth Rate |
CAGR of 3.0% |
| Historical Year |
2018 to 2022 (Data from 2010 can be provided as per availability) |
| Base Year |
2022 |
| Forecast Year |
2030 |
| Number of Pages |
110 Pages |
| Customization Available |
Yes, the report can be customized as per your need. |
TABLE OF CONTENTS
1 Introduction to Research & Analysis Reports
1.1 Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Market Definition
1.2 Market Segments
1.2.1 Market by Type
1.2.2 Market by Application
1.3 Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Overall Market Size
2.1 Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Market Size: 2022 VS 2030
2.2 Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Revenue, Prospects & Forecasts: 2018-2030
2.3 Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales: 2018-2030
3 Company Landscape
3.1 Top Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Players in Global Market
3.2 Top Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Companies Ranked by Revenue
3.3 Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Revenue by Companies
3.4 Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales by Companies
3.5 Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Price by Manufacturer (2018-2023)
3.6 Top 3 and Top 5 Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Companies in Global Market, by Revenue in 2022
3.7 Global Manufacturers Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Product Type
3.8 Tier 1, Tier 2 and Tier 3 Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Players in Global Market
3.8.1 List of Global Tier 1 Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Companies
3.8.2 List of Global Tier 2 and Tier 3 Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Companies
4 Sights by Product
4.1 Overview
4.1.1 By Type - Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Market Size Markets, 2022 & 2030
4.1.2 60 KIU
4.1.3 50 KIU
4.2 By Type - Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Revenue & Forecasts
4.2.1 By Type - Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Revenue, 2018-2023
4.2.2 By Type - Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Revenue, 2024-2030
4.2.3 By Type - Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Revenue Market Share, 2018-2030
4.3 By Type - Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales & Forecasts
4.3.1 By Type - Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales, 2018-2023
4.3.2 By Type - Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales, 2024-2030
4.3.3 By Type - Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales Market Share, 2018-2030
4.4 By Type - Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Price (Manufacturers Selling Prices), 2018-2030
5 Sights by Application
5.1 Overview
5.1.1 By Application - Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Market Size, 2022 & 2030
5.1.2 Bleeding
5.1.3 Surgery Assisted
5.1.4 Glanzmann Plateletasthenia
5.1.5 Hemophilia B
5.1.6 Hemophilia A
5.1.7 Head Trauma
5.1.8 Others
5.2 By Application - Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Revenue & Forecasts
5.2.1 By Application - Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Revenue, 2018-2023
5.2.2 By Application - Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Revenue, 2024-2030
5.2.3 By Application - Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Revenue Market Share, 2018-2030
5.3 By Application - Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales & Forecasts
5.3.1 By Application - Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales, 2018-2023
5.3.2 By Application - Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales, 2024-2030
5.3.3 By Application - Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales Market Share, 2018-2030
5.4 By Application - Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Price (Manufacturers Selling Prices), 2018-2030
6 Sights by Region
6.1 By Region - Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Market Size, 2022 & 2030
6.2 By Region - Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Revenue & Forecasts
6.2.1 By Region - Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Revenue, 2018-2023
6.2.2 By Region - Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Revenue, 2024-2030
6.2.3 By Region - Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Revenue Market Share, 2018-2030
6.3 By Region - Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales & Forecasts
6.3.1 By Region - Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales, 2018-2023
6.3.2 By Region - Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales, 2024-2030
6.3.3 By Region - Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales Market Share, 2018-2030
6.4 North America
6.4.1 By Country - North America Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Revenue, 2018-2030
6.4.2 By Country - North America Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales, 2018-2030
6.4.3 US Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Market Size, 2018-2030
6.4.4 Canada Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Market Size, 2018-2030
6.4.5 Mexico Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Market Size, 2018-2030
6.5 Europe
6.5.1 By Country - Europe Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Revenue, 2018-2030
6.5.2 By Country - Europe Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales, 2018-2030
6.5.3 Germany Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Market Size, 2018-2030
6.5.4 France Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Market Size, 2018-2030
6.5.5 U.K. Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Market Size, 2018-2030
6.5.6 Italy Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Market Size, 2018-2030
6.5.7 Russia Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Market Size, 2018-2030
6.5.8 Nordic Countries Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Market Size, 2018-2030
6.5.9 Benelux Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Market Size, 2018-2030
6.6 Asia
6.6.1 By Region - Asia Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Revenue, 2018-2030
6.6.2 By Region - Asia Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales, 2018-2030
6.6.3 China Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Market Size, 2018-2030
6.6.4 Japan Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Market Size, 2018-2030
6.6.5 South Korea Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Market Size, 2018-2030
6.6.6 Southeast Asia Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Market Size, 2018-2030
6.6.7 India Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Market Size, 2018-2030
6.7 South America
6.7.1 By Country - South America Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Revenue, 2018-2030
6.7.2 By Country - South America Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales, 2018-2030
6.7.3 Brazil Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Market Size, 2018-2030
6.7.4 Argentina Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Market Size, 2018-2030
6.8 Middle East & Africa
6.8.1 By Country - Middle East & Africa Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Revenue, 2018-2030
6.8.2 By Country - Middle East & Africa Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales, 2018-2030
6.8.3 Turkey Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Market Size, 2018-2030
6.8.4 Israel Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Market Size, 2018-2030
6.8.5 Saudi Arabia Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Market Size, 2018-2030
6.8.6 UAE Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Market Size, 2018-2030
7 Manufacturers & Brands Profiles
7.1 BMS
7.1.1 BMS Company Summary
7.1.2 BMS Business Overview
7.1.3 BMS Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Major Product Offerings
7.1.4 BMS Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales and Revenue in Global (2018-2023)
7.1.5 BMS Key News & Latest Developments
7.2 Generium
7.2.1 Generium Company Summary
7.2.2 Generium Business Overview
7.2.3 Generium Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Major Product Offerings
7.2.4 Generium Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales and Revenue in Global (2018-2023)
7.2.5 Generium Key News & Latest Developments
7.3 Novo Nordisk
7.3.1 Novo Nordisk Company Summary
7.3.2 Novo Nordisk Business Overview
7.3.3 Novo Nordisk Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Major Product Offerings
7.3.4 Novo Nordisk Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales and Revenue in Global (2018-2023)
7.3.5 Novo Nordisk Key News & Latest Developments
7.4 Shire (Baxter)
7.4.1 Shire (Baxter) Company Summary
7.4.2 Shire (Baxter) Business Overview
7.4.3 Shire (Baxter) Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Major Product Offerings
7.4.4 Shire (Baxter) Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales and Revenue in Global (2018-2023)
7.4.5 Shire (Baxter) Key News & Latest Developments
7.5 Bayer
7.5.1 Bayer Company Summary
7.5.2 Bayer Business Overview
7.5.3 Bayer Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Major Product Offerings
7.5.4 Bayer Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales and Revenue in Global (2018-2023)
7.5.5 Bayer Key News & Latest Developments
7.6 CSL
7.6.1 CSL Company Summary
7.6.2 CSL Business Overview
7.6.3 CSL Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Major Product Offerings
7.6.4 CSL Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales and Revenue in Global (2018-2023)
7.6.5 CSL Key News & Latest Developments
7.7 Pfizer
7.7.1 Pfizer Company Summary
7.7.2 Pfizer Business Overview
7.7.3 Pfizer Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Major Product Offerings
7.7.4 Pfizer Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales and Revenue in Global (2018-2023)
7.7.5 Pfizer Key News & Latest Developments
7.8 Grifols
7.8.1 Grifols Company Summary
7.8.2 Grifols Business Overview
7.8.3 Grifols Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Major Product Offerings
7.8.4 Grifols Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales and Revenue in Global (2018-2023)
7.8.5 Grifols Key News & Latest Developments
7.9 Biogen
7.9.1 Biogen Company Summary
7.9.2 Biogen Business Overview
7.9.3 Biogen Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Major Product Offerings
7.9.4 Biogen Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales and Revenue in Global (2018-2023)
7.9.5 Biogen Key News & Latest Developments
7.10 Octapharma
7.10.1 Octapharma Company Summary
7.10.2 Octapharma Business Overview
7.10.3 Octapharma Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Major Product Offerings
7.10.4 Octapharma Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales and Revenue in Global (2018-2023)
7.10.5 Octapharma Key News & Latest Developments
7.11 NovoNordisk
7.11.1 NovoNordisk Company Summary
7.11.2 NovoNordisk Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Business Overview
7.11.3 NovoNordisk Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Major Product Offerings
7.11.4 NovoNordisk Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales and Revenue in Global (2018-2023)
7.11.5 NovoNordisk Key News & Latest Developments
7.12 Greencross
7.12.1 Greencross Company Summary
7.12.2 Greencross Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Business Overview
7.12.3 Greencross Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Major Product Offerings
7.12.4 Greencross Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales and Revenue in Global (2018-2023)
7.12.5 Greencross Key News & Latest Developments
7.13 Kedrion
7.13.1 Kedrion Company Summary
7.13.2 Kedrion Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Business Overview
7.13.3 Kedrion Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Major Product Offerings
7.13.4 Kedrion Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales and Revenue in Global (2018-2023)
7.13.5 Kedrion Key News & Latest Developments
7.14 BPL
7.14.1 BPL Company Summary
7.14.2 BPL Business Overview
7.14.3 BPL Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Major Product Offerings
7.14.4 BPL Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales and Revenue in Global (2018-2023)
7.14.5 BPL Key News & Latest Developments
7.15 Hualan Bio
7.15.1 Hualan Bio Company Summary
7.15.2 Hualan Bio Business Overview
7.15.3 Hualan Bio Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Major Product Offerings
7.15.4 Hualan Bio Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales and Revenue in Global (2018-2023)
7.15.5 Hualan Bio Key News & Latest Developments
7.16 RAAS
7.16.1 RAAS Company Summary
7.16.2 RAAS Business Overview
7.16.3 RAAS Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Major Product Offerings
7.16.4 RAAS Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales and Revenue in Global (2018-2023)
7.16.5 RAAS Key News & Latest Developments
7.17 Suzhou Alphamab
7.17.1 Suzhou Alphamab Company Summary
7.17.2 Suzhou Alphamab Business Overview
7.17.3 Suzhou Alphamab Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Major Product Offerings
7.17.4 Suzhou Alphamab Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales and Revenue in Global (2018-2023)
7.17.5 Suzhou Alphamab Key News & Latest Developments
8 Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Production Capacity, Analysis
8.1 Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Production Capacity, 2018-2030
8.2 Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Production Capacity of Key Manufacturers in Global Market
8.3 Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Production by Region
9 Key Market Trends, Opportunity, Drivers and Restraints
9.1 Market Opportunities & Trends
9.2 Market Drivers
9.3 Market Restraints
10 Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Supply Chain Analysis
10.1 Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Industry Value Chain
10.2 Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Upstream Market
10.3 Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Downstream and Clients
10.4 Marketing Channels Analysis
10.4.1 Marketing Channels
10.4.2 Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Distributors and Sales Agents in Global
11 Conclusion
12 Appendix
12.1 Note
12.2 Examples of Clients
12.3 Disclaimer
LIST OF TABLES & FIGURES
List of Tables
Table 1. Key Players of Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) in Global Market
Table 2. Top Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Players in Global Market, Ranking by Revenue (2022)
Table 3. Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Revenue by Companies, (US$, Mn), 2018-2023
Table 4. Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Revenue Share by Companies, 2018-2023
Table 5. Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales by Companies, (K Units), 2018-2023
Table 6. Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales Share by Companies, 2018-2023
Table 7. Key Manufacturers Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Price (2018-2023) & (US$/Unit)
Table 8. Global Manufacturers Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Product Type
Table 9. List of Global Tier 1 Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Companies, Revenue (US$, Mn) in 2022 and Market Share
Table 10. List of Global Tier 2 and Tier 3 Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Companies, Revenue (US$, Mn) in 2022 and Market Share
Table 11. By Type ? Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Revenue, (US$, Mn), 2022 & 2030
Table 12. By Type - Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Revenue (US$, Mn), 2018-2023
Table 13. By Type - Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Revenue (US$, Mn), 2024-2030
Table 14. By Type - Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales (K Units), 2018-2023
Table 15. By Type - Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales (K Units), 2024-2030
Table 16. By Application ? Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Revenue, (US$, Mn), 2022 & 2030
Table 17. By Application - Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Revenue (US$, Mn), 2018-2023
Table 18. By Application - Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Revenue (US$, Mn), 2024-2030
Table 19. By Application - Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales (K Units), 2018-2023
Table 20. By Application - Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales (K Units), 2024-2030
Table 21. By Region ? Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Revenue, (US$, Mn), 2022 VS 2030
Table 22. By Region - Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Revenue (US$, Mn), 2018-2023
Table 23. By Region - Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Revenue (US$, Mn), 2024-2030
Table 24. By Region - Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales (K Units), 2018-2023
Table 25. By Region - Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales (K Units), 2024-2030
Table 26. By Country - North America Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Revenue, (US$, Mn), 2018-2023
Table 27. By Country - North America Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Revenue, (US$, Mn), 2024-2030
Table 28. By Country - North America Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales, (K Units), 2018-2023
Table 29. By Country - North America Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales, (K Units), 2024-2030
Table 30. By Country - Europe Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Revenue, (US$, Mn), 2018-2023
Table 31. By Country - Europe Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Revenue, (US$, Mn), 2024-2030
Table 32. By Country - Europe Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales, (K Units), 2018-2023
Table 33. By Country - Europe Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales, (K Units), 2024-2030
Table 34. By Region - Asia Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Revenue, (US$, Mn), 2018-2023
Table 35. By Region - Asia Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Revenue, (US$, Mn), 2024-2030
Table 36. By Region - Asia Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales, (K Units), 2018-2023
Table 37. By Region - Asia Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales, (K Units), 2024-2030
Table 38. By Country - South America Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Revenue, (US$, Mn), 2018-2023
Table 39. By Country - South America Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Revenue, (US$, Mn), 2024-2030
Table 40. By Country - South America Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales, (K Units), 2018-2023
Table 41. By Country - South America Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales, (K Units), 2024-2030
Table 42. By Country - Middle East & Africa Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Revenue, (US$, Mn), 2018-2023
Table 43. By Country - Middle East & Africa Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Revenue, (US$, Mn), 2024-2030
Table 44. By Country - Middle East & Africa Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales, (K Units), 2018-2023
Table 45. By Country - Middle East & Africa Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales, (K Units), 2024-2030
Table 46. BMS Company Summary
Table 47. BMS Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Product Offerings
Table 48. BMS Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales (K Units), Revenue (US$, Mn) and Average Price (US$/Unit) (2018-2023)
Table 49. BMS Key News & Latest Developments
Table 50. Generium Company Summary
Table 51. Generium Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Product Offerings
Table 52. Generium Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales (K Units), Revenue (US$, Mn) and Average Price (US$/Unit) (2018-2023)
Table 53. Generium Key News & Latest Developments
Table 54. Novo Nordisk Company Summary
Table 55. Novo Nordisk Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Product Offerings
Table 56. Novo Nordisk Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales (K Units), Revenue (US$, Mn) and Average Price (US$/Unit) (2018-2023)
Table 57. Novo Nordisk Key News & Latest Developments
Table 58. Shire (Baxter) Company Summary
Table 59. Shire (Baxter) Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Product Offerings
Table 60. Shire (Baxter) Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales (K Units), Revenue (US$, Mn) and Average Price (US$/Unit) (2018-2023)
Table 61. Shire (Baxter) Key News & Latest Developments
Table 62. Bayer Company Summary
Table 63. Bayer Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Product Offerings
Table 64. Bayer Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales (K Units), Revenue (US$, Mn) and Average Price (US$/Unit) (2018-2023)
Table 65. Bayer Key News & Latest Developments
Table 66. CSL Company Summary
Table 67. CSL Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Product Offerings
Table 68. CSL Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales (K Units), Revenue (US$, Mn) and Average Price (US$/Unit) (2018-2023)
Table 69. CSL Key News & Latest Developments
Table 70. Pfizer Company Summary
Table 71. Pfizer Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Product Offerings
Table 72. Pfizer Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales (K Units), Revenue (US$, Mn) and Average Price (US$/Unit) (2018-2023)
Table 73. Pfizer Key News & Latest Developments
Table 74. Grifols Company Summary
Table 75. Grifols Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Product Offerings
Table 76. Grifols Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales (K Units), Revenue (US$, Mn) and Average Price (US$/Unit) (2018-2023)
Table 77. Grifols Key News & Latest Developments
Table 78. Biogen Company Summary
Table 79. Biogen Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Product Offerings
Table 80. Biogen Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales (K Units), Revenue (US$, Mn) and Average Price (US$/Unit) (2018-2023)
Table 81. Biogen Key News & Latest Developments
Table 82. Octapharma Company Summary
Table 83. Octapharma Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Product Offerings
Table 84. Octapharma Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales (K Units), Revenue (US$, Mn) and Average Price (US$/Unit) (2018-2023)
Table 85. Octapharma Key News & Latest Developments
Table 86. NovoNordisk Company Summary
Table 87. NovoNordisk Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Product Offerings
Table 88. NovoNordisk Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales (K Units), Revenue (US$, Mn) and Average Price (US$/Unit) (2018-2023)
Table 89. NovoNordisk Key News & Latest Developments
Table 90. Greencross Company Summary
Table 91. Greencross Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Product Offerings
Table 92. Greencross Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales (K Units), Revenue (US$, Mn) and Average Price (US$/Unit) (2018-2023)
Table 93. Greencross Key News & Latest Developments
Table 94. Kedrion Company Summary
Table 95. Kedrion Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Product Offerings
Table 96. Kedrion Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales (K Units), Revenue (US$, Mn) and Average Price (US$/Unit) (2018-2023)
Table 97. Kedrion Key News & Latest Developments
Table 98. BPL Company Summary
Table 99. BPL Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Product Offerings
Table 100. BPL Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales (K Units), Revenue (US$, Mn) and Average Price (US$/Unit) (2018-2023)
Table 101. BPL Key News & Latest Developments
Table 102. Hualan Bio Company Summary
Table 103. Hualan Bio Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Product Offerings
Table 104. Hualan Bio Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales (K Units), Revenue (US$, Mn) and Average Price (US$/Unit) (2018-2023)
Table 105. Hualan Bio Key News & Latest Developments
Table 106. RAAS Company Summary
Table 107. RAAS Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Product Offerings
Table 108. RAAS Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales (K Units), Revenue (US$, Mn) and Average Price (US$/Unit) (2018-2023)
Table 109. RAAS Key News & Latest Developments
Table 110. Suzhou Alphamab Company Summary
Table 111. Suzhou Alphamab Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Product Offerings
Table 112. Suzhou Alphamab Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales (K Units), Revenue (US$, Mn) and Average Price (US$/Unit) (2018-2023)
Table 113. Suzhou Alphamab Key News & Latest Developments
Table 114. Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Production Capacity (K Units) of Key Manufacturers in Global Market, 2021-2023 (K Units)
Table 115. Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Capacity Market Share of Key Manufacturers, 2021-2023
Table 116. Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Production by Region, 2018-2023 (K Units)
Table 117. Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Production by Region, 2024-2030 (K Units)
Table 118. Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Market Opportunities & Trends in Global Market
Table 119. Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Market Drivers in Global Market
Table 120. Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Market Restraints in Global Market
Table 121. Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Raw Materials
Table 122. Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Raw Materials Suppliers in Global Market
Table 123. Typical Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Downstream
Table 124. Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Downstream Clients in Global Market
Table 125. Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Distributors and Sales Agents in Global Market
List of Figures
Figure 1. Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Segment by Type in 2022
Figure 2. Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Segment by Application in 2022
Figure 3. Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Market Overview: 2022
Figure 4. Key Caveats
Figure 5. Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Market Size: 2022 VS 2030 (US$, Mn)
Figure 6. Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Revenue, 2018-2030 (US$, Mn)
Figure 7. Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales in Global Market: 2018-2030 (K Units)
Figure 8. The Top 3 and 5 Players Market Share by Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Revenue in 2022
Figure 9. By Type - Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Revenue, (US$, Mn), 2022 & 2030
Figure 10. By Type - Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Revenue Market Share, 2018-2030
Figure 11. By Type - Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales Market Share, 2018-2030
Figure 12. By Type - Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Price (US$/Unit), 2018-2030
Figure 13. By Application - Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Revenue, (US$, Mn), 2022 & 2030
Figure 14. By Application - Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Revenue Market Share, 2018-2030
Figure 15. By Application - Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales Market Share, 2018-2030
Figure 16. By Application - Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Price (US$/Unit), 2018-2030
Figure 17. By Region - Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Revenue, (US$, Mn), 2022 & 2030
Figure 18. By Region - Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Revenue Market Share, 2018 VS 2022 VS 2030
Figure 19. By Region - Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Revenue Market Share, 2018-2030
Figure 20. By Region - Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales Market Share, 2018-2030
Figure 21. By Country - North America Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Revenue Market Share, 2018-2030
Figure 22. By Country - North America Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales Market Share, 2018-2030
Figure 23. US Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Revenue, (US$, Mn), 2018-2030
Figure 24. Canada Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Revenue, (US$, Mn), 2018-2030
Figure 25. Mexico Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Revenue, (US$, Mn), 2018-2030
Figure 26. By Country - Europe Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Revenue Market Share, 2018-2030
Figure 27. By Country - Europe Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales Market Share, 2018-2030
Figure 28. Germany Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Revenue, (US$, Mn), 2018-2030
Figure 29. France Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Revenue, (US$, Mn), 2018-2030
Figure 30. U.K. Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Revenue, (US$, Mn), 2018-2030
Figure 31. Italy Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Revenue, (US$, Mn), 2018-2030
Figure 32. Russia Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Revenue, (US$, Mn), 2018-2030
Figure 33. Nordic Countries Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Revenue, (US$, Mn), 2018-2030
Figure 34. Benelux Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Revenue, (US$, Mn), 2018-2030
Figure 35. By Region - Asia Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Revenue Market Share, 2018-2030
Figure 36. By Region - Asia Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales Market Share, 2018-2030
Figure 37. China Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Revenue, (US$, Mn), 2018-2030
Figure 38. Japan Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Revenue, (US$, Mn), 2018-2030
Figure 39. South Korea Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Revenue, (US$, Mn), 2018-2030
Figure 40. Southeast Asia Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Revenue, (US$, Mn), 2018-2030
Figure 41. India Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Revenue, (US$, Mn), 2018-2030
Figure 42. By Country - South America Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Revenue Market Share, 2018-2030
Figure 43. By Country - South America Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales Market Share, 2018-2030
Figure 44. Brazil Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Revenue, (US$, Mn), 2018-2030
Figure 45. Argentina Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Revenue, (US$, Mn), 2018-2030
Figure 46. By Country - Middle East & Africa Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Revenue Market Share, 2018-2030
Figure 47. By Country - Middle East & Africa Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Sales Market Share, 2018-2030
Figure 48. Turkey Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Revenue, (US$, Mn), 2018-2030
Figure 49. Israel Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Revenue, (US$, Mn), 2018-2030
Figure 50. Saudi Arabia Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Revenue, (US$, Mn), 2018-2030
Figure 51. UAE Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Revenue, (US$, Mn), 2018-2030
Figure 52. Global Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Production Capacity (K Units), 2018-2030
Figure 53. The Percentage of Production Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) by Region, 2022 VS 2030
Figure 54. Eptacog Alfa (Recombinant Human Coagulation Factor VIIa) Industry Value Chain
Figure 55. Marketing Channels
